3,0
9. Dez. 2016
Ehemaliger Mitarbeiter, mehr als 10 Jahre
Raleigh, NC
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Pharma will always be lucrative as long as they keep the development pipeline full of assets that can go onto successful trials, and there lies the Achilles heel of the industry. That and CEO issues and law suits.
Kontras
GSK slaughtered its R&D presence in NC over a decade. Once a predominate tenant in the Research Park area, GSK left its employees with pro-rated severances and the area with shells of empty buildings for off-shored and contracted work. One excuse actually given in 2014, 'real-estate was cheaper in Philly.'